Industry Webcast

Basal Insulin: When to Initiate Therapy in Type 2 DiabetesIndustry Webcast Sponsored by Sanofi; Not for CME/CE Credit

This virtual session will delve into the crucial role  of basal insulin in the management of type 2 diabetes; participants will explore key aspects relating to type 2 diabetes treatment, including the negative health impact of delaying treatment intensification in people not at target, when and how to start and titrate basal insulin, including practical pointers to facilitate timely initiation and individualization. The session will also touch on the distinguishing characteristics of available basal insulin, in particular, longer- and long-acting analogs and a case study will be used throughout to highlight considerations from the patient perspective.


Disclosures for Speakers:
The following relevant financial relationships have been disclosed by faculty and have been mitigated by Pri-Med Institute:

Eugene E. Wright, Jr., MD: Advisor for Abbott Diabetes Care, Ascencia, Bayer, Boehringer Ingelheim, Embecta, Lilly LLC, and Sanofi; Consultant for Abbott Diabetes Care, Bayer, Boehringer Ingelheim, Embecta, Lilly LLC, and Sanofi; Speaker for Abbott Diabetes Care, Bayer, Boehringer Ingelheim, Lilly LLC, and Sanofi.

Jennifer Goldman, RPh, PharmD, CDCES, BC-ADM, FCCP: Speaker for Abbott Diabetes Care, Amgen, CeQur, Lilly LLC, Novo Nordisk, Sanofi, and Xeris.
Non-faculty contributors and others involved in the planning, development, editing, and review of the content have disclosed no relevant financial relationships.